Predict your next investment

Corporation
toxicreports.com

See what CB Insights has to offer

About Toxic Reports

Toxic Reports offers analytical services for rapid testing of persistent organic pollutants (POPs) in food and the environment. The company's franchise laboratories are ISO 17025 accredited providing high quality analytical testing of Persistent organic pollutants (POPs). Unlike other analytical labs which offer analytical services for everything, Toxic Reports focus is POPs. Toxic Reports uses the power of advanced analytical instrumentation combined with automated sample preparation create the world's fastest, lowest cost, highest quality expertise in high resolution (HR/MS) Testing.

Toxic Reports Headquarter Location

580 Pleasant Street

Watertown, Massachusetts, 02472,

United States

617-393-1713

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Toxic Reports News

Toxic Reports

Oct 1, 2015

Verify here. The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com. All rights reserved. All other trademarks recognized. Copyright © 1997-2015 BioPortfolio Limited. Site developed by Alacrify Ltd .

Toxic Reports Acquisitions

1 Acquisition

Toxic Reports acquired 1 company. Their latest acquisition was PathoGenetix on February 13, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/13/2015

Series C

$99M

$117.71M

Asset Sale

1

Date

2/13/2015

Investment Stage

Series C

Companies

Valuation

$99M

Total Funding

$117.71M

Note

Asset Sale

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.